共 50 条
- [21] Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinibLEUKEMIA RESEARCH, 2019, 79 : 38 - 44Gerds, Aaron T.Tauchi, TetsuzoRitchie, EllenDeininger, MichaelJamieson, CatrionaMesa, RubenHeaney, MarkKomatsu, NorioMinami, HironobuSu, YunShaik, NaveedZhang, XiaoxiDiRienzo, ChristineZeremski, MirjanaChan, GeoffreyTalpaz, Moshe
- [22] MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK InhibitorCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S339 - S340Mesa, RubenGerds, AaronVannucchi, AlessandroAl-Ali, Haifa KathrinLavie, DavidKuykendall, AndrewGrosicki, SebastianIurlo, AlessandraGoh, Yeow TeeLazaroiu, MihaelaEgyed, MiklosFox, Maria LauraMcLornan, DonalPerkins, AndrewYoon, Sung-SooGupta, VikasKiladjian, Jean-JacquesDonahue, RafeKawashima, JunVerstovsek, Srdan
- [23] Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Winton, Elliott F.Devos, TimothyOh, Stephen T.Platzbecker, UweWadleigh, MarthaJun, SusieLee, PeterDeng, WeiGupta, Vikas
- [24] MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Mesa, Ruben A.Gerds, Aaron ThomasVannucchi, AlessandroAl-Ali, Haifa KathrinLavie, DavidKuykendall, Andrew T.Grosicki, SebastianIurlo, AlessandraGoh, Yeow TeeLazaroiu, Mihaela CorneliaEgyed, MiklosFox, Maria LauraMcLornan, Donal P.Perkins, AndrewYoon, Sung-SooGupta, VikasKiladjian, Jean-JacquesDonahue, RafeKawashima, JunVerstovsek, Srdan
- [25] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)BLOOD, 2020, 136Dilley, KimberleyHarb, JasonJalaluddin, MuhammadHutti, Jessica E.Potluri, Jalaja
- [26] Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialBLOOD, 2022, 140 : 1781 - 1783Harrison, ClaireNangalia, JyotiBoucher, Rebecca H.Jackson, AimeeYap, ChristinaO'Sullivan, JenniferFox, SoniaAilts, IsaakDueck, Amylou C.Geyer, Holly L.Mesa, RubenDunn, WilliamNadezhdin, EugeneCurto-Garcia, NataliaGreen, AnnaWilkins, BridgetCoppell, JasonLaurie, JohnGarg, MamtaEwing, JoanneKnapper, SteveCrowe, JosephineKoutsavlis, IoannisGodfrey, Anna L.Arami, SiamakDrummond, Mark W.Byrne, JenniferClark, Fiona J.Mead-Harvey, CarolynBaxter, Joanna E.McMullin, Mary FrancesMead, Adam J.
- [27] PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), IN PATIENTS WITH MYELOFIBROSIS (MF) AND BASELINE (BL) THROMBOCYTOPENIA: FOCUS ON RUXOLITINIB (RUX)-TREATED PATIENTS IN THE PHASE 3 PERSIST-2 TRIALHAEMATOLOGICA, 2017, 102 : 280 - 281Harrison, C.Mascarenhas, J.Hoffman, R.Talpaz, M.Gerds, A. T.Stein, B.Gupta, V.Szoke, A.Drummond, M.Pristupa, A.Granston, T.Daly, R.Al-Fayoumi, S.Callahan, J. A.Singer, J. W.Gotlib, J.Jamieson, C.Mesa, R.Verstovsek, S.
- [28] Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorBLOOD, 2022, 140 : 1514 - 1517Gerds, Aaron T.Mesa, RubenVannucchi, Alessandro M.Al-Ali, Haifa KathrinLavie, DavidKuykendall, AndrewGrosicki, SebastianIurlo, AlessandraGoh, Yeow TeeLazaroiu, MihaelaEgyed, MiklosFox, Maria LauraMcLornan, Donal P.Perkins, Andrew CharlesYoon, Sung-SooGupta, VikasKiladjian, Jean-JacquesDonahue, RafeKawashima, JunVerstovsek, Srdan
- [29] Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect ComparisonBLOOD, 2024, 144 : 3187 - 3188Palandri, FrancescaKapetanakis, VenediktosDobi, BalazsBranzanti, FilippoEllis, CatherineBallew, NickLiu, TomPhiri, KelesitseSen Nikitas, FulyaBiasi, MelaniaZhang, ShiyuanPatnaik, Dwaipayan
- [30] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized TrialJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3534 - +Harrison, Claire N.Nangalia, JyotiBoucher, RebeccaJackson, AimeeYap, ChristinaO'Sullivan, JenniferFox, SoniaAilts, IsaakDueck, Amylou C.Geyer, Holly L.Mesa, Ruben A.Dunn, William G.Nadezhdin, EugeneCurto-Garcia, NataliaGreen, AnnaWilkins, BridgetCoppell, JasonLaurie, JohnGarg, MamtaEwing, JoanneKnapper, StevenCrowe, JosephineChen, FrederickKoutsavlis, IoannisGodfrey, AnnaArami, SiamakDrummond, MarkByrne, JenniferClark, FionaMead-Harvey, CarolynBaxter, Elizabeth JoannaMcMullin, Mary FrancesMead, Adam J.